FONAR (FONR) 10-Q 10 Feb 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Dec. 31, 2014	Jan. 31, 2015
Entity Registrant Name	Fonar Corporation
Entity Central Index Key	355019
Document Type	10-Q
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-24
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015
Common Stock
Entity Common Stock, Shares Outstanding		6,050,840
Class B Common Stock
Entity Common Stock, Shares Outstanding		146
Class C Common Stock
Entity Common Stock, Shares Outstanding		382,513
Preferred Stock Class A
Entity Common Stock, Shares Outstanding		313,438

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$11,674	$9,952
Accounts receivable - net	5,028	4,450
Accounts receivable - Related party	60
Medical receivables -net	8,898	8,808
Management and other fees receivable -net	13,740	11,970
Management and other fees receivable - related medical practices -net	3,469	3,427
Costs and estimated earnings in excess of billings on uncompleted contracts	726	760
Inventories	2,363	2,444
Prepaid expenses and other current assets	823	1,011
Total Current Assets	46,781	42,822
Deferred income tax asset	5,740	5,740
Property and equipment - net	13,951	15,030
Goodwill	1,767	1,767
Other intangible assets - net	9,933	10,509
Other assets	868	922
Total Assets	79,040	76,790
Current Liabilities:
Current portion of long-term debt and capital leases	2,894	2,891
Accounts payable	2,397	2,482
Other current liabilities	8,470	9,024
Unearned revenue on service contracts	5,052	4,731
Unearned revenue on service contracts - related parties	55
Customer advances	1,819	1,927
Billings in excess of costs and estimated earnings on uncompleted contracts	168	142
Total Current Liabilities	20,855	21,197
Long-Term Liabilities:
Deferred income tax liability	584	584
Due to related medical practices	229	234
Long-term debt and capital leases, less current portion	6,935	8,482
Other liabilities	217	386
Total Long-Term Liabilities	7,965	9,686
Total Liabilities	28,820	30,883
STOCKHOLDERS' EQUITY:
Common Stock	1	1
Paid-in capital in excess of par value	175,413	175,284
Accumulated deficit	-144,066	-149,259
Notes receivable from employee stockholders	-35	-39
Treasury stock, at cost - 12 shares of common stock at December 31, 2014 and June 30, 2014	-675	-675
Total Fonar Corporation Stockholder Equity	30,638	25,312
Noncontrolling interests	19,582	20,595
Total Stockholders' Equity	50,220	45,907
Total Liabilities and Stockholders' Equity	$79,040	$76,790

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Jun. 30, 2014
Class A NonVoting Preferred Stock
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Authorized	453,000	453,000
Preferred Stock, Issued	313,000	313,000
Preferred Stock, Outstanding	313,000	313,000
Preferred Stock
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Authorized	567,000	567,000
Preferred Stock, Issued
Preferred Stock, Outstanding
Common Stock
Common Stock, Par Value	$0.00	$0.00
Common Stock, Authorized	8,500,000	8,500,000
Common Stock, Issued	6,062,000	6,057,000
Common Stock, Outstanding	6,051,000	6,046,000
Class B Common Stock
Common Stock, Par Value	$0.00	$0.00
Common Stock, Authorized	227,000	227,000
Common Stock, Issued	146	146
Common Stock, Outstanding	146	146
Class C Common Stock
Common Stock, Par Value	$0.00	$0.00
Common Stock, Authorized	567,000	567,000
Common Stock, Issued	383,000	383,000
Common Stock, Outstanding	383,000	383,000

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
REVENUES
Product sales - net	$375	$755	$1,646	$783
Service and repair fees - net	2,499	2,548	4,989	5,060
Service and repair fees - related parties - net	28	28	55	55
Patient fee revenue, net of contractual allowances and discounts	6,629	5,894	13,416	11,721
Provision for bad debts for patient fee	-2,897	-2,223	-6,042	-4,262
Management and other fees - net	8,613	8,274	17,351	16,417
Management and other fees - related medical practices - net	1,845	2,333	3,662	4,666
Total Revenues - Net	17,092	17,609	35,077	34,440
COSTS AND EXPENSES
Costs related to product sales	237	631	1,322	678
Costs related to service and repair fees	474	587	981	1,131
Costs related to service and repair fees - related parties	5	6	11	12
Costs related to patient fee revenue	1,902	2,028	3,801	3,877
Costs related to management and other fees	5,180	5,190	10,379	10,264
Costs related to management and other fees - related medical practices	1,240	1,270	2,609	2,490
Research and development	359	374	756	769
Selling, general and administrative	3,824	4,352	7,403	8,089
Provision for bad debts	273	-124	779	-218
Total Costs and Expenses	13,494	14,314	28,041	27,092
Income From Operations	3,598	3,295	7,036	7,348
Interest Expense	-172	-237	-376	-480
Investment Income	60	60	122	121
Other Expense	-2		-2	-151
Income Before Provision for Income Taxes and noncontrolling Interests	3,484	3,118	6,780	6,838
Provision for Income Taxes	29	70	69	170
Net Income	3,455	3,048	6,711	6,668
Net Income - Noncontrolling Interests	-797	-905	-1,518	-2,088
Net Income - Controlling Interests	2,658	2,143	5,193	4,580
Basic Net Income Per Common Share	$0.44	$0.36	$0.86	$0.76
Weighted Average Basic Shares Outstanding	6,051,000	6,006,000	6,050,000	5,992,000
Common Stock
COSTS AND EXPENSES
Net Income - Controlling Interests	2,485	2,003	4,856	4,280
Basic Net Income Per Common Share	$0.41	$0.33	$0.80	$0.71
Diluted Net Income Per Common Share	$0.40	$0.33	$0.79	$0.70
Weighted Average Basic Shares Outstanding	6,051,000	6,006,000	6,050,000	5,992,000
Weighted Average Diluted Shares Outstanding	6,179,000	6,133,000	6,178,000	6,120,000
Preferred Stock Class A
COSTS AND EXPENSES
Net Income - Controlling Interests	129	104	251	223
Class C Common Stock
COSTS AND EXPENSES
Net Income - Controlling Interests	$44	$36	$86	$77
Basic Net Income Per Common Share	$0.12	$0.09	$0.22	$0.20
Diluted Net Income Per Common Share	$0.12	$0.09	$0.22	$0.20
Weighted Average Basic Shares Outstanding	383,000	383,000	383,000	383,000
Weighted Average Diluted Shares Outstanding	383,000	383,000	383,000	383,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities:
Net income	$6,711	$6,668
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,776	1,954
Provision for bad debts	6,820	4,044
Non-cash considerations	76	155
Compensatory element of stock issuances	53	86
(Increase) decrease in operating assets, net:
Accounts, management fee and medical receivable(s)	-9,360	-7,261
Notes receivable	103	60
Costs and estimated earnings in excess of billings on uncompleted contracts	34	-609
Inventories	80	-485
Prepaid expenses and other current assets	131	210
Other assets	8	42
Increase (decrease) in operating liabilities, net:
Accounts payable	-84	189
Other current liabilities	-178	1,580
Customer advances	-108	183
Billings in excess of costs and estimated earnings on uncompleted contracts	26
Other liabilities	-169	-58
Due to related medical practices	-6	-2
Income tax payable		-20
Net cash provided by operating activities	5,913	6,767
Cash Flows from Investing Activities:
Purchases of property and equipment	-55	-277
Cost of patents	-67	-58
Net cash used in investing activities	-122	-335
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations	-1,543	-2,195
Distributions to noncontrolling interests	-2,530	-2,696
Repayment of notes receivable from employee stockholders	4	13
Net cash used in financing activities	-4,069	-4,878
Net Increase in Cash and Cash Equivalents	1,722	1,554
Cash and Cash Equivalents - Beginning of Period	9,952	7,871
Cash and Cash Equivalents - End of Period	$11,674	$9,425

NOTE_1_BASIS_OF_PRESENTATION_U

NOTE 1 - BASIS OF PRESENTATION (USD $)	6 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
NOTE 1 - BASIS OF PRESENTATION & LIQUIDITY & CAPITAL RESOURCES	NOTE 1 - BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2014, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2015. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on September 29, 2014 for the fiscal year ended June 30, 2014.

NOTE_2_SUMMARY_OF_SIGNIFICANT_

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (USD $)	6 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.
	Earnings Per Share
	Basic earnings per share (“EPS”) is computed based on the weighted average number of shares common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the three and six months ended December 31, 2014 and December 31, 2013.
	Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2014 and December 31, 2013, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.
		Three months ended						Three months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	2,658	$	2,485	$	44	$	2,143	$	2,003	$	36
	Denominator:
	Weighted average shares outstanding		6,051		6,051		383		6,006		6,006		383
	Basic income per common  share	$	0.44	$	0.41	$	0.12	$	0.36	$	0.33	$	0.09
	Diluted
	Denominator:
	Weighted average shares outstanding				6,051		383				6,006		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,179		383				6,133		383
	Diluted income per common share			$	0.4	$	0.12			$	0.33	$	0.09
		Six months ended						Six months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	5,193	$	4,856	$	86	$	4,580	$	4,280	$	77
	Denominator:
	Weighted average shares outstanding		6,050		6,050		383		5,992		5,992		383
	Basic income per common share	$	0.86	$	0.8	$	0.22	$	0.76	$	0.71	$	0.2
	Diluted
	Denominator:
	Weighted average shares outstanding				6,050		383				5,992		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,178		383				6,120		383
	Diluted income per common share			$	0.79	$	0.22			$	0.7	$	0.2
	Recent Accounting Pronouncements
	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
	FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2014 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2014 or 2013, and it does not believe that any of those pronouncements will have a significant impact on our condensed consolidated financial statements at the time they become effective.
	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifcations did not have any effect on reported consolidated net income for any periods presented.

NOTE_3_ACCOUNTS_RECEIVABLE_MED

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $)	6 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
NOTE 3 - ACCOUNTS RECEIVABLE. MEDICAL RECEIVABLES AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $)	NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE
	Receivables, net is comprised of the following at December 31, 2014:
		Accounts Receivable			Allowance for doubtful accounts			Net
	Accounts receivable	$	5,330		$	302		$	5,028
	Accounts receivable - related party	$	60			—		$	60
	Medical receivables	$	27,858		$	18,960		$	8,898
	Management and other fees receivable	$	25,375		$	11,635		$	13,740
	Management and other fees receivable from related medical practices ("PC’s")	$	3,872		$	403		$	3,469
	Receivables, net is comprised of the following at June 30, 2014:
		Accounts Receivable			Allowance for doubtful accounts			Net
	Accounts receivable	$	4,707		$	257		$	4,450
	Accounts receivable - related party	$	—			—		$	—
	Medical receivable	$	21,726		$	12,918		$	8,808
	Management and other fees receivable	$	22,872		$	10,902		$	11,970
	Management and other fees receivable from related medical practices ("PC’s")	$	3,830		$	403		$	3,427
	The Company's customers are concentrated in the healthcare industry.
	Accounts Receivable
	Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided.
	Medical Receivables
	Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company continuously monitors collections from its clients and maintains an allowance for bad debts based upon the Company’s historical collection experience. The Company determines uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site.
	Management and Other Fees Receivable
	The Company's receivables from the related and non-related professional corporations (PC's) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC's of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.
	Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 52% and 49% of the PCs’ net revenues for the three months ended December 31, 2014 and 2013, respectively, were derived from no-fault and personal injury protection claims. Approximately 53% and 50% of the PCs’ net revenues for the six months ended December 31, 2014 and 2013, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management's expectations.
	Net revenues from management and other fees charged to the related PCs accounted for approximately 10.8% and 13.2% of the consolidated net revenues for the three months ended December 31, 2014 and 2013, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately 10.4% and 13.5% of the consolidated net revenues for the six months ended December 31, 2014 and 2013, respectively.
	Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement.
	The Company’s patient fee revenue, net of contractual allowances and discounts less the provision for bad debts for the three and six months ended December 31, 2014 and 2013 are summarized in the following tables.
		For the Three Months Ended December 31,
		2014			2013
	Commercial Insurance/ Managed Care	$	1,074		$	1,011
	Medicare/Medicaid		307			439
	Workers' Compensation/Personal Injury		3,146			3,455
	Other		2,102			989
	Patient Fee Revenue, net of contractual allowances and discounts		6,629			5,894
	Provision for Bad Debts		(2,897	)		(2,223	)
	Net Patient Fee for Revenue	$	3,732		$	3,671
		For the Six Months Ended December 31,
		2014			2013
	Commercial Insurance/ Managed Care	$	2,154		$	2,111
	Medicare/Medicaid		604			818
	Workers' Compensation/Personal Injury		6,841			6,350
	Other		3,817			2,442
	Patient Fee Revenue, net of contractual allowances and discounts		13,416			11,721
	Provision for Bad Debts		(6,042	)		(4,262	)
	Net Patient Fee for Revenue	$	7,374		$	7,459

NOTE_4_INVENTORIES

NOTE 4 - INVENTORIES	6 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
NOTE 4 - INVENTORIES	NOTE 4 - INVENTORIES
	Inventories included in the accompanying condensed consolidated balance sheet consist of the following:
		31-Dec-14		30-Jun-14
	Purchased parts, components   and supplies	$	2,170	$	2,094
	Work-in-process		193		350
	Total Inventories	$	2,363	$	2,444

NOTE_5_COSTS_AND_ESTIMATED_EAR

NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS	6 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS	NOTE 5 – COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS
	Information relating to uncompleted contracts is as follows:
		31-Dec-14		30-Jun-14
	Costs incurred on uncompleted contracts	$	2,973	$	1,885
	Estimated earnings		2,252		1,746
	Subtotal		5,225		3,631
	Less: Billings to date		4,667		3,013
	Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	558	$	618
	Included in the accompanying condensed consolidated balance sheets under the following captions:
		31-Dec-14		30-Jun-14
	Costs and estimated earnings in excess of billings on uncompleted contracts	$	726	$	760
	Less: Billings in excess of costs and estimated earnings on uncompleted contracts		168		142
	Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	558		618

NOTE_6_OTHER_INTANGIBLE_ASSETS

NOTE 6 - OTHER INTANGIBLE ASSETS	6 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
NOTE 6 - OTHER INTANGIBLE ASSETS	NOTE 6 – OTHER INTANGIBLE ASSETS
	Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheet consist of the following:
		December 31,		June 30,
		2014		2014
	Capitalized software development costs	$	7,418	$	7,418
	Patents and copyrights		4,475		4,408
	Non-compete		4,100		4,100
	Customer relationships		3,800		3,800
	Gross Other intangible assets		19,793		19,726
	Less: Accumulated amortization		9,860		9,217
	Other Intangible Assets	$	9,933	$	10,509
	Amortization of patents and copyrights for the three months ended December 31, 2014 and 2013 amounted to $46 and $45, respectively.
	Amortization of capitalized software development costs for the three months ended December 31, 2014 and 2013 amounted to $81 and $108, respectively.
	Amortization of non-compete for the three months ended December 31, 2014 and 2013 amounted to $147 and $147, respectively.
	Amortization of customer relationships for the three months ended December 31, 2014 and 2013 amounted to $47 and $48, respectively.
	Amortization of patents and copyrights for the six months ended December 31, 2014 and 2013 amounted to $91 and $89, respectively.
	Amortization of capitalized software development costs for the six months ended December 31, 2014 and 2013 amounted to $164 and $217, respectively.
	Amortization of non-compete for the six months ended December 31, 2014 and 2013 amounted to $293 and $293, respectively.
	Amortization of customer relationships for the six months ended December 31, 2014 and 2013 amounted to $95 and $92, respectively.

NOTE_7_OTHER_CURRENT_LIABILITI

NOTE 7 - OTHER CURRENT LIABILITIES	6 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
NOTE 7 - OTHER CURRENT LIABILITIES	NOTE 7 – OTHER CURRENT LIABILITIES
	Other current liabilities in the accompanying condensed consolidated balance sheet consist of the following:
		31-Dec-14		30-Jun-14
	Accrued salaries, commissions and payroll taxes	$	767	$	835
	Accrued interest		117		117
	Litigation accruals		589		664
	Sales tax payable		2,569		2,665
	Legal and other professional fees		409		439
	Accounting fees		168		325
	Self-funded health insurance reserve		390		306
	Interest and penalty - sales tax		2,415		2,374
	Purchase scanners		100		450
	Other		946		849
	Total Other Current Liabilities	$	8,470	$	9,024

NOTE_8_STOCKHOLDERS_EQUITY

NOTE 8 - STOCKHOLDERS EQUITY	6 Months Ended
	Dec. 31, 2014
Equity [Abstract]
NOTE 8 - STOCKHOLDERS EQUITY	NOTE 8 – STOCKHOLDERS EQUITY
	Common Stock
	During the six months ended December 31, 2014, the Company issued 5 shares of common stock to employees and consultants as compensation valued at $53 under a stock bonus plan.

NOTE_9_SEGMENT_AND_RELATED_INF

NOTE 9 - SEGMENT AND RELATED INFORMATION	6 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
NOTE 9 - SEGMENT AND RELATED INFORMATION	NOTE 9 - SEGMENT AND RELATED INFORMATION
	The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.
	The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2014. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.
	Summarized financial information concerning the Company's reportable segments is shown in the following table:
		Medical Equipment			Management Of Diagnostic Imaging Centers		Totals
	For the three months ended December 31, 2014
	Net revenues from external customers	$	2,902		$	14,190	$	17,092
	Inter-segment net revenues	$	501		$	—	$	501
	Income from operations	$	446		$	3,152	$	3,598
	Depreciation and amortization	$	75		$	813	$	888
	Capital expenditures	$	21		$	29	$	50
	For the three months ended December 31, 2013
	Net revenues from external customers	$	3,331		$	14,278	$	17,609
	Inter-segment net revenues	$	495		$	—	$	495
	Income from operations	$	(31	)	$	3,326	$	3,295
	Depreciation and amortization	$	60		$	912	$	972
	Capital expenditures	$	26		$	80	$	106
	For the six months ended December 31, 2014
	Net revenues from external customers	$	6,690		$	28,387	$	35,077
	Inter-segment net revenues	$	1,002		$	—	$	1,002
	Income from operations	$	824		$	6,212	$	7,036
	Depreciation and amortization	$	151		$	1,625	$	1,776
	Capital expenditures	$	67		$	55	$	122
	For the six months ended December 31, 2013
	Net revenues from external customers	$	5,898		$	28,542	$	34,440
	Inter-segment net revenues	$	990		$	—	$	990
	Income from operations	$	131		$	7,217	$	7,348
	Depreciation and amortization	$	218		$	1,736	$	1,954
	Capital expenditures	$	73		$	262	$	335

NOTE_10_SUPPLEMENTAL_CASH_FLOW

NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 10– SUPPLEMENTAL CASH FLOW INFORMATION
	During the six months ended December 31, 2014 and December 31, 2013, the Company paid $284 and $361 for interest, respectively.
	During the six months ended December 31, 2014 and December 31, 2013, the Company paid $69 and $190 for income taxes, respectively.

NOTE_11_COMMITMENTS_AND_CONTIN

NOTE 11 - COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
NOTE 11 - COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES
	Litigation
	The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.
	There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2014 and our form 10-Q for the first quarter of fiscal 2015.
	Other Matters
	The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of December 31, 2014, the Company has recorded tax obligations of approximately $2,569 plus interest and penalties of approximately $2,415. The Company is in the process of determining the regulatory requirements in order to become compliant.
	The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third party insurer to limit the maximum potential liability for individual claims to $100 per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of December 31, 2014 and June 30, 2014, the Company had approximately $390 and $306, respectively, in reserve for its self-funded health insurance programs. The reserves are included in “Other current liabilities” in the condensed consolidated balance sheets.
	The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report

NOTE_12_INCOME_TAXES

NOTE 12 - INCOME TAXES	6 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
NOTE 12 - INCOME TAXES	NOTE 12 - INCOME TAXES
	ASC topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC topic 740.
	In accordance with ASC topic 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net”. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses.
	The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2009.
	The Company recorded a deferred tax asset of $5,740 and a deferred tax liability of $584 as of December 31, 2014, primarily relating to net operating loss carryforwards of approximately $137,252 available to offset future taxable income through 2034. The net operating losses begin to expire in 2019 for federal tax purposes and in 2014 for state income tax purposes.
	The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. At present, the Company does have a sufficient history of income and anticipates profitability in the coming years and has concluded that it is more-likely-than-not that the Company will be able to realize a portion of its tax benefits in the near future and therefore a valuation allowance was established for the partial value of the deferred tax asset.
	A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of any portion or all of the valuation. Should the Company continue to remain profitable in future periods with supportable trends, the valuation allowance will be reversed accordingly.

NOTE_13_SUBSEQUENT_EVENTS

NOTE 13 - SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
NOTE 13 - SUBSEQUENT EVENTS	NOTE 13- SUBSEQUENT EVENTS
	On January 8, 2015, the Company purchased 20% of the Class A members ownership interest in Health Diagnostic Management LLC for a cost of $4,971. After this transaction, the Company has a 60.4% ownership interest

NOTE_2_SUMMARY_OF_SIGNIFICANT_1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2014
Note 2 - Summary Of Significant Accounting Policies Policies
Principles of Consolidation	Principles of Consolidation
	The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.
Earnings Per Share	Earnings Per Share
	Basic earnings per share (“EPS”) is computed based on the weighted average number of shares common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the three and six months ended December 31, 2014 and December 31, 2013.
	Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three and six months ended December 31, 2014 and December 31, 2013, diluted EPS for common shareholders includes 128 shares upon conversion of Class C Common.
		Three months ended						Three months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	2,658	$	2,485	$	44	$	2,143	$	2,003	$	36
	Denominator:
	Weighted average shares outstanding		6,051		6,051		383		6,006		6,006		383
	Basic income per common  share	$	0.44	$	0.41	$	0.12	$	0.36	$	0.33	$	0.09
	Diluted
	Denominator:
	Weighted average shares outstanding				6,051		383				6,006		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,179		383				6,133		383
	Diluted income per common share			$	0.4	$	0.12			$	0.33	$	0.09
		Six months ended						Six months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	5,193	$	4,856	$	86	$	4,580	$	4,280	$	77
	Denominator:
	Weighted average shares outstanding		6,050		6,050		383		5,992		5,992		383
	Basic income per common share	$	0.86	$	0.8	$	0.22	$	0.76	$	0.71	$	0.2
	Diluted
	Denominator:
	Weighted average shares outstanding				6,050		383				5,992		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,178		383				6,120		383
	Diluted income per common share			$	0.79	$	0.22			$	0.7	$	0.2
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supercedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
	FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2014 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2014 or 2013, and it does not believe that any of those pronouncements will have a significant impact on our condensed consolidated financial statements at the time they become effective.
Reclassifications	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifcations did not have any effect on reported consolidated net income for any periods presented.

NOTE_2_SUMMARY_OF_SIGNIFICANT_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Earnings Per Share
		Three months ended						Three months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	2,658	$	2,485	$	44	$	2,143	$	2,003	$	36
	Denominator:
	Weighted average shares outstanding		6,051		6,051		383		6,006		6,006		383
	Basic income per common  share	$	0.44	$	0.41	$	0.12	$	0.36	$	0.33	$	0.09
	Diluted
	Denominator:
	Weighted average shares outstanding				6,051		383				6,006		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,179		383				6,133		383
	Diluted income per common share			$	0.4	$	0.12			$	0.33	$	0.09
		Six months ended						Six months ended
		31-Dec-14						31-Dec-13
	Basic		Total		Common Stock		Class C Common Stock		Total		Common Stock		Class C Common Stock
	Numerator:
	Net income available to common stockholders	$	5,193	$	4,856	$	86	$	4,580	$	4,280	$	77
	Denominator:
	Weighted average shares outstanding		6,050		6,050		383		5,992		5,992		383
	Basic income per common share	$	0.86	$	0.8	$	0.22	$	0.76	$	0.71	$	0.2
	Diluted
	Denominator:
	Weighted average shares outstanding				6,050		383				5,992		383
	Stock options				—		—				—		—
	Convertible Class C Stock				128		—				128		—
	Total Denominator for diluted earnings per share				6,178		383				6,120		383
	Diluted income per common share			$	0.79	$	0.22			$	0.7	$	0.2

NOTE_3_ACCOUNTS_RECEIVABLE_MED1

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (USD $) (Tables)	6 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Receivables - net	Receivables, net is comprised of the following at December 31, 2014:
		Accounts Receivable			Allowance for doubtful accounts			Net
	Accounts receivable	$	5,330		$	302		$	5,028
	Accounts receivable - related party	$	60			—		$	60
	Medical receivables	$	27,858		$	18,960		$	8,898
	Management and other fees receivable	$	25,375		$	11,635		$	13,740
	Management and other fees receivable from related medical practices ("PC’s")	$	3,872		$	403		$	3,469
	Receivables, net is comprised of the following at June 30, 2014:
		Accounts Receivable			Allowance for doubtful accounts			Net
	Accounts receivable	$	4,707		$	257		$	4,450
	Accounts receivable - related party	$	—			—		$	—
	Medical receivable	$	21,726		$	12,918		$	8,808
	Management and other fees receivable	$	22,872		$	10,902		$	11,970
	Management and other fees receivable from related medical practices ("PC’s")	$	3,830		$	403		$	3,427
	The Company's customers are concentrated in the healthcare industry.
Patient fee revenue - net	Patient fee revenue - net
		For the Three Months Ended December 31,
		2014			2013
	Commercial Insurance/ Managed Care	$	1,074		$	1,011
	Medicare/Medicaid		307			439
	Workers' Compensation/Personal Injury		3,146			3,455
	Other		2,102			989
	Patient Fee Revenue, net of contractual allowances and discounts		6,629			5,894
	Provision for Bad Debts		(2,897	)		(2,223	)
	Net Patient Fee for Revenue	$	3,732		$	3,671
		For the Six Months Ended December 31,
		2014			2013
	Commercial Insurance/ Managed Care	$	2,154		$	2,111
	Medicare/Medicaid		604			818
	Workers' Compensation/Personal Injury		6,841			6,350
	Other		3,817			2,442
	Patient Fee Revenue, net of contractual allowances and discounts		13,416			11,721
	Provision for Bad Debts		(6,042	)		(4,262	)
	Net Patient Fee for Revenue	$	7,374		$	7,459

NOTE_4_INVENTORIES_Tables

NOTE 4 - INVENTORIES (Tables)	6 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
		31-Dec-14		30-Jun-14
	Purchased parts, components   and supplies	$	2,170	$	2,094
	Work-in-process		193		350
	Total Inventories	$	2,363	$	2,444

NOTE_5_COSTS_AND_ESTIMATED_EAR1

NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS (Tables)	6 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
Information relating to uncompleted contracts	Information relating to uncompleted contracts
		31-Dec-14		30-Jun-14
	Costs incurred on uncompleted contracts	$	2,973	$	1,885
	Estimated earnings		2,252		1,746
	Subtotal		5,225		3,631
	Less: Billings to date		4,667		3,013
	Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	558	$	618
Included in the accompanying condensed consolidated balance sheets	Included in the accompanying condensed consolidated balance sheets
		31-Dec-14		30-Jun-14
	Costs and estimated earnings in excess of billings on uncompleted contracts	$	726	$	760
	Less: Billings in excess of costs and estimated earnings on uncompleted contracts		168		142
	Total Costs and estimated earnings in excess of billings on uncompleted contracts	$	558		618

NOTE_6_OTHER_INTANGIBLE_ASSETS1

NOTE 6 - OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Other intangible assets - net	Other intangible assets - net
		December 31,		June 30,
		2014		2014
	Capitalized software development costs	$	7,418	$	7,418
	Patents and copyrights		4,475		4,408
	Non-compete		4,100		4,100
	Customer relationships		3,800		3,800
	Gross Other intangible assets		19,793		19,726
	Less: Accumulated amortization		9,860		9,217
	Other Intangible Assets	$	9,933	$	10,509

NOTE_7_OTHER_CURRENT_LIABILITI1

NOTE 7 - OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Other current liabilities	Other current liabilities
		31-Dec-14		30-Jun-14
	Accrued salaries, commissions and payroll taxes	$	767	$	835
	Accrued interest		117		117
	Litigation accruals		589		664
	Sales tax payable		2,569		2,665
	Legal and other professional fees		409		439
	Accounting fees		168		325
	Self-funded health insurance reserve		390		306
	Interest and penalty - sales tax		2,415		2,374
	Purchase scanners		100		450
	Other		946		849
	Total Other Current Liabilities	$	8,470	$	9,024

NOTE_9_SEGMENT_AND_RELATED_INF1

NOTE 9 - SEGMENT AND RELATED INFORMATION (Tables)	6 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment information	Segment Information
		Medical Equipment			Management Of Diagnostic Imaging Centers		Totals
	For the three months ended December 31, 2014
	Net revenues from external customers	$	2,902		$	14,190	$	17,092
	Inter-segment net revenues	$	501		$	—	$	501
	Income from operations	$	446		$	3,152	$	3,598
	Depreciation and amortization	$	75		$	813	$	888
	Capital expenditures	$	21		$	29	$	50
	For the three months ended December 31, 2013
	Net revenues from external customers	$	3,331		$	14,278	$	17,609
	Inter-segment net revenues	$	495		$	—	$	495
	Income from operations	$	(31	)	$	3,326	$	3,295
	Depreciation and amortization	$	60		$	912	$	972
	Capital expenditures	$	26		$	80	$	106
	For the six months ended December 31, 2014
	Net revenues from external customers	$	6,690		$	28,387	$	35,077
	Inter-segment net revenues	$	1,002		$	—	$	1,002
	Income from operations	$	824		$	6,212	$	7,036
	Depreciation and amortization	$	151		$	1,625	$	1,776
	Capital expenditures	$	67		$	55	$	122
	For the six months ended December 31, 2013
	Net revenues from external customers	$	5,898		$	28,542	$	34,440
	Inter-segment net revenues	$	990		$	—	$	990
	Income from operations	$	131		$	7,217	$	7,348
	Depreciation and amortization	$	218		$	1,736	$	1,954
	Capital expenditures	$	73		$	262	$	335

NOTE_2_SUMMARY_OF_SIGNIFICANT_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Basic Numerator: Net income available to common stockholders	$2,658	$2,143	$5,193	$4,580
Basic Denominator: Weighted average shares outstanding	6,051,000	6,006,000	6,050,000	5,992,000
Basic Income Per Common Share	$0.44	$0.36	$0.86	$0.76
Convertible Class C Stock	128,000	128,000	128,000	128,000
Common Stock
Basic Numerator: Net income available to common stockholders	2,485	2,003	4,856	4,280
Basic Denominator: Weighted average shares outstanding	6,051,000	6,006,000	6,050,000	5,992,000
Basic Income Per Common Share	$0.41	$0.33	$0.80	$0.71
Stock options
Convertible Class C Stock	128,000	128,000	128,000	128,000
Total Denominator for diluted earnings per share	6,179,000	6,133,000	6,178,000	6,120,000
Diluted Income Per Share	$0.40	$0.33	$0.79	$0.70
Class C Common Stock
Basic Numerator: Net income available to common stockholders	$44	$36	$86	$77
Basic Denominator: Weighted average shares outstanding	383,000	383,000	383,000	383,000
Basic Income Per Common Share	$0.12	$0.09	$0.22	$0.20
Stock options
Convertible Class C Stock
Total Denominator for diluted earnings per share	383,000	383,000	383,000	383,000
Diluted Income Per Share	$0.12	$0.09	$0.22	$0.20

NOTE_3_ACCOUNTS_RECEIVABLE_MED2

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Receivables, Net - (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Accounts receivable	$5,028	$4,450
Accounts receivable - Related party	60
Medical Receivables	8,898	8,808
Management and other fees receivable	13,740	11,970
Management and other fees receivable from related medical practices ("PC's")	3,469	3,427
Accounts Receivable [Member]
Accounts receivable	5,330	4,707
Accounts receivable - Related party	60
Medical Receivables	27,858	21,726
Management and other fees receivable	25,375	22,872
Management and other fees receivable from related medical practices ("PC's")	3,872	3,830
Allowance for Doubtful Accounts, Current
Accounts receivable	302	257
Accounts receivable - Related party
Medical Receivables	18,960	12,918
Management and other fees receivable	11,635	10,902
Management and other fees receivable from related medical practices ("PC's")	$403	$403

NOTE_3_ACCOUNTS_RECEIVABLE_MED3

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Patient Fees Revenue - (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Patient fee revenue, net of contractual allowances and discounts	$6,629	$5,894	$13,416	$11,721
Provision for bad debts for patient fee	-2,897	-2,223	-6,042	-4,262
Net patient fee revenue	3,732	3,671	7,374	7,459
Commercial Insurance / Managed Care
Patient fee revenue, net of contractual allowances and discounts	1,074	1,011	2,154	2,111
Medicare/Medicaid
Patient fee revenue, net of contractual allowances and discounts	307	439	604	818
Workers Compensation/Personal Injury
Patient fee revenue, net of contractual allowances and discounts	3,146	3,455	6,841	6,350
Other
Patient fee revenue, net of contractual allowances and discounts	$2,102	$989	$3,817	$2,442

NOTE_4_INVENTORIES_Details

NOTE 4 - INVENTORIES (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Total inventories	$2,363	$2,444
InventoriesMember
Purchased parts, components and supplies	2,170	2,094
Work-in-process	193	350
Total inventories	$2,363	$2,444

NOTE_5_COSTS_AND_ESTIMATED_EAR2

NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Information relating to uncompleted contracts - (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Notes to Financial Statements
Costs incurred on uncompleted contracts	$2,973	$1,885
Estimated earnings	2,252	1,746
Subtotal	5,225	3,631
Less: Billings to date	4,667	3,013
Total Costs and estimated earnings in excess of billings on uncompleted contracts	$558	$618

NOTE_5_COSTS_AND_ESTIMATED_EAR3

NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS - Balance Sheet Items - (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Note 5 - Costs And Estimated Earnings On Uncompleted Contracts - Balance Sheet Items - Details
Costs and estimated earnings in excess of billings on uncompleted contracts	$726	$760
Less: Billings in excess of costs and estimated earnings on uncompleted contracts	168	142
Total Costs and estimated earnings in excess of billings on uncompleted contracts	$558	$618

NOTE_6_OTHER_INTANGIBLE_ASSETS2

NOTE 6 - OTHER INTANGIBLE ASSETS - (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Accumulated Amortization	$9,860	$9,217
Intangible asset value, net	9,933	10,509
Software Development Costs
Intangible asset value, gross	7,418	7,418
Patents and copyrights
Intangible asset value, gross	4,475	4,408
Non-compete Agreements
Intangible asset value, gross	4,100	4,100
Customer Relationships
Intangible asset value, gross	3,800	3,800
Other Intangible Assets
Intangible asset value, gross	$19,793	$19,726

NOTE_7_OTHER_CURRENT_LIABILITI2

NOTE 7 - OTHER CURRENT LIABILITIES - (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$767	$835
Accrued interest	117	117
Litigation accruals	589	664
Sales tax payable	2,569	2,665
Legal and other professional fees	409	439
Accounting fees	168	325
Self-funded health insurance reserve	390	306
Interest and penalty - sales tax	2,415	2,374
Purchase Scanners	100	450
Other	946	849
Total Other current liabilities	$8,470	$9,024

NOTE_9_SEGMENT_AND_RELATED_INF2

NOTE 9 - SEGMENT AND RELATED INFORMATION - Segment Information - (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Net revenues from external customers	$17,092	$17,609	$35,077	$34,440
Inter-segment net revenues	501	495	1,002	990
Income from operations	3,598	3,295	7,036	7,348
Depreciation and amortization	888	972	1,776	1,954
Capital expenditures	50	106	122	335
Medical Equipment
Net revenues from external customers	2,902	3,331	6,690	5,898
Inter-segment net revenues	501	495	1,002	990
Income from operations	446	-31	824	131
Depreciation and amortization	75	60	151	218
Capital expenditures	21	26	67	73
Management Of Diagnostic Imaging Centers
Net revenues from external customers	14,190	14,278	28,387	28,542
Inter-segment net revenues
Income from operations	3,152	3,326	6,212	7,217
Depreciation and amortization	813	912	1,625	1,736
Capital expenditures	$29	$80	$55	$262

NOTE_2_SUMMARY_OF_SIGNIFICANT_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Details Narrative)	3 Months Ended		6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Shares included upon conversion of Class C Common to calculate a diluted EPS	128,000	128,000	128,000	128,000

NOTE_3_ACCOUNTS_RECEIVABLE_MED4

NOTE 3 - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - (Details Narrative)	3 Months Ended		6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Note 3 - Accounts Receivable Medical Receivable And Management And Other Fees Receivable - Details Narrative
Net revenues derived from no-fault and personal injury protection claims	52.00%	49.00%	53.00%	50.00%
Net revenues from management and other fees charged to related PCs	10.80%	13.20%	10.40%	13.50%

NOTE_6_OTHER_INTANGIBLE_ASSETS3

NOTE 6 - OTHER INTANGIBLE ASSETS - (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Patents and copyrights
Amortization of intangible assets	$46	$45	$91	$89
Software Development Costs
Amortization of intangible assets	81	108	164	217
Non-compete Agreements
Amortization of intangible assets	147	147	293	293
Customer Relationships
Amortization of intangible assets	$47	$48	$95	$925

NOTE_8_STOCKHOLDERS_EQUITY_Det

NOTE 8 - STOCKHOLDERS EQUITY - (Details Narrative) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Equity [Abstract]
Common shares issued for compensation (shares)	5,000
Common shares issued for compensation ($)	$53

NOTE_10_SUPPLEMENTAL_CASH_FLOW1

NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION ($)- (Details Narrative) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Note 10 - Supplemental Cash Flow Information - Details Narrative
Interest paid	$284	$361
Income Taxes Paid	$69	$190

NOTE_11_COMMITMENTS_AND_CONTIN1

NOTE 11 - COMMITMENTS AND CONTINGENCIES - (Details Narrative) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
Recorded tax obligations	$2,569
Tax interest and penalties	2,415
Maximum limit for individual claims under stop-loss umbrella policy for health insurance	100
Self-funded health insurance reserve	$390	$306

NOTE_12_INCOME_TAXES_Details_N

NOTE 12 - INCOME TAXES - (Details Narrative) (USD $)	Dec. 31, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Deferred income tax asset	$5,740	$5,740
Deferred income tax liability	584	584
Net deferred operating loss carryforwards	$137,252

NOTE_13_SUBSEQUENT_EVENTS_Deta

NOTE 13- SUBSEQUENT EVENTS - (Details Narrative) (USD $)	Jan. 08, 2015
In Thousands, unless otherwise specified
Note 13- Subsequent Events - Details Narrative
Company purchased Class A members ownership interest in Health Diagnostic Management, LLC (%)	20.00%
Company purchase price for 20% ownership in Health Diagnostic Management, LLC ($)	$4,971
Current Company ownership of Health Diagnostic Management, LLC (%)	60.40%